The inflammatory cytokine TNFα cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Leibovich Rivkin, Tal ^a   Liubomirski, Yulia ^a   Meshel, Tsipi ^a   Abashidze, Anastasia ^a   Brisker, Daphna ^a   Solomon, Hilla ^b   Rotter, Varda ^b   Weil, Miguel ^a   Ben Baruch, Adit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

CXCL8; Interleukin 1 ; p53; Ras; Tumor necrosis factor

Indexed keywords

BINDING PROTEIN; CHEMOKINE; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN P53; RAS PROTEIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; TYROSINE KINASE RECEPTOR; GUANOSINE TRIPHOSPHATE; PROTEIN BINDING; PROTEIN P21; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1;

ARTICLE; BREAST CANCER; CANCER PATIENT; CELL STRAIN MCF 7; CHORIOALLANTOIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPH NODE METASTASIS; METASTASIS; PHENOTYPE; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; TUMOR GROWTH; TUMOR PROMOTION; WESTERN BLOTTING; ANIMAL; CHEMISTRY; CHICK EMBRYO; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; MCF 7 CELL LINE; METABOLISM; MOUSE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; TUMOR CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER GROWTH; CARCINOGENESIS; CXCL8 GENE; DOWN REGULATION; LUCIFERASE ASSAY; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WILD TYPE;

ANIMALS; CELL LINE, TUMOR; CHICK EMBRYO; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GUANOSINE TRIPHOSPHATE; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-8; MAP KINASE SIGNALING SYSTEM; MCF-7 CELLS; MICE; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899492082     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-158     Document Type: Article

References (68)

1. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008, 9(7):517-531. 10.1038/nrm2438, 3915522, 18568040.
2. Blum R, Cox AD, Kloog Y. Inhibitors of chronically active ras: potential for treatment of human malignancies. Recent Pat Anticancer Drug Discov 2008, 3(1):31-47. 10.2174/157489208783478702, 18289122.
3. Goldstein I, Marcel V, Olivier M, Oren M, Rotter V, Hainaut P. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther 2011, 18(1):2-11. 10.1038/cgt.2010.63, 20966976.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674. 10.1016/j.cell.2011.02.013, 21376230.
5. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009, 9(4):239-252. 10.1038/nrc2618, 3251309, 19279573.
6. Balkwill F, Mantovani A. Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther 2010, 87(4):401-406. 10.1038/clpt.2009.312, 20200512.
7. Witz IP. The tumor microenvironment: the making of a paradigm. Cancer Microenviron 2009, 2(Suppl 1):9-17.
8. Balkwill FR. The chemokine system and cancer. J Pathol 2012, 226(2):148-157. 10.1002/path.3029, 21989643.
9. Leibovich-Rivkin TBY, Solomon H, Meshel T, Rotter V, Ben-Baruch A. Tumor-promoting circuits that regulate a cancer-related chemokine cluster: dominance of inflammatory mediators over oncogenic alterations. Cancers 2012, 4:55-76. 10.3390/cancers4010055, 3712671, 24213226.
10. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008, 14(21):6735-6741. 10.1158/1078-0432.CCR-07-4843, 18980965.
11. Ali S, Lazennec G. Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev 2007, 26(3-4):401-420. 2668792, 17717637.
12. Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 2008, 267(2):271-285. 10.1016/j.canlet.2008.03.018, 18439751.
13. Yadav A, Saini V, Arora S. MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta 2010, 411(21-22):1570-1579.
14. Conti I, Rollins BJ. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol 2004, 14(3):149-154. 10.1016/j.semcancer.2003.10.009, 15246049.
15. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009, 9(5):361-371. 10.1038/nrc2628, 19343034.
16. Ben-Baruch A. The tumor-promoting flow of cells into, within and out of the tumor site: regulation by the inflammatory axis of TNFalpha and chemokines. Cancer Microenviron 2011, 5(2):151-164. 3399063, 22190050.
17. Dinarello CA. Why not treat human cancer with interleukin-1 blockade?. Cancer Metastasis Rev 2010, 29(2):317-329. 10.1007/s10555-010-9229-0, 2865633, 20422276.
18. Apte RN, Voronov E. Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy?. Immunol Rev 2008, 222:222-241. 10.1111/j.1600-065X.2008.00615.x, 18364005.
19. Bertazza L, Mocellin S. The dual role of tumor necrosis factor (TNF) in cancer biology. Curr Med Chem 2010, 17(29):3337-3352. 10.2174/092986710793176339, 20712570.
20. Mocellin S, Nitti D. TNF and cancer: the two sides of the coin. Front Biosci 2008, 13:2774-2783. 10.2741/2884, 17981752.
21. Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T, Weitzenfeld P, Meshel T, Shabtai E, Gutman M, Ben-Baruch A. Inflammatory mediators in breast cancer: coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 2011, 11:130-149. 10.1186/1471-2407-11-130, 3095565, 21486440.
22. Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A, Schwall R, Schnitt SJ, Guida A, Hastings HM, Andres J, Turkel G, Polverini PJ, Goldberg ID, Rosen EM. Expression of interleukin-1beta in human breast carcinoma. Cancer 1997, 80(3):421-434. 10.1002/(SICI)1097-0142(19970801)80:3<421::AID-CNCR10>3.0.CO;2-Z, 9241076.
23. Warren MA, Shoemaker SF, Shealy DJ, Bshar W, Ip MM. Tumor necrosis factor deficiency inhibits mammary tumorigenesis and a tumor necrosis factor neutralizing antibody decreases mammary tumor growth in neu/erbB2 transgenic mice. Mol Cancer Ther 2009, 8(9):2655-2663. 10.1158/1535-7163.MCT-09-0358, 19755514.
24. Hamaguchi T, Wakabayashi H, Matsumine A, Sudo A, Uchida A. TNF inhibitor suppresses bone metastasis in a breast cancer cell line. Biochem Biophys Res Commun 2011, 407(3):525-530. 10.1016/j.bbrc.2011.03.051, 21414299.
25. Reed JR, Leon RP, Hall MK, Schwertfeger KL. Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis. Breast Cancer Res 2009, 11(2):R21. 10.1186/bcr2246, 2688950, 19393083.
26. Schmid MC, Avraamides CJ, Foubert P, Shaked Y, Kang SW, Kerbel RS, Varner JA. Combined blockade of integrin-alpha4beta1 plus cytokines SDF-1alpha or IL-1beta potently inhibits tumor inflammation and growth. Cancer Res 2011, 71(22):6965-6975. 10.1158/0008-5472.CAN-11-0588, 3249446, 21948958.
27. Katz M, Amit I, Yarden Y. Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta 2007, 1773(8):1161-1176. 10.1016/j.bbamcr.2007.01.002, 2758354, 17306385.
28. Janes PW, Daly RJ, de Fazio A, Sutherland RL. Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 1994, 9(12):3601-3608.
29. Omerovic J, Hammond DE, Clague MJ, Prior IA. Ras isoform abundance and signalling in human cancer cell lines. Oncogene 2008, 27(19):2754-2762. 10.1038/sj.onc.1210925, 2557550, 17998936.
30. Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, Ng SS, French PJ, Peeters JK, Rozendaal MJ, Riaz M, Koopman DG, Ten Hagen TL, de Leeuw BH, Zwarthoff EC, Teunisse A, van der Spek PJ, Klijn JG, Dinjens WN, Ethier SP, Clevers H, Jochemsen AG, den Bakker MA, Foekens JA, Martens JW, Schutte M. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat 2010, 121(1):53-64. 10.1007/s10549-009-0460-8, 19593635.
31. Neumark E, Sagi-Assif O, Shalmon B, Ben-Baruch A, Witz IP. Progression of mouse mammary tumors: MCP-1-TNFalpha cross-regulatory pathway and clonal expression of promalignancy and antimalignancy factors. Int J Cancer 2003, 106(6):879-886. 10.1002/ijc.11337, 12918065.
32. Seeger H, Wallwiener D, Mueck AO. Effects of estradiol and progestogens on tumor-necrosis factor-alpha-induced changes of biochemical markers for breast cancer growth and metastasis. Gynecol Endocrinol 2008, 24(10):576-579. 10.1080/09513590802288267, 19012101.
33. De Larco JE, Wuertz BR, Rosner KA, Erickson SA, Gamache DE, Manivel JC, Furcht LT. A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am J Pathol 2001, 158(2):639-646. 10.1016/S0002-9440(10)64005-9, 1850317, 11159200.
34. Pantschenko AG, Pushkar I, Miller LJ, Wang YP, Anderson K, Peled Z, Kurtzman SH, Kreutzer DL. In vitro demonstration of breast cancer tumor cell sub-populations based on interleukin-1/tumor necrosis factor induction of interleukin-8 expression. Oncol Rep 2003, 10(4):1011-1017.
35. Cataisson C, Ohman R, Patel G, Pearson A, Tsien M, Jay S, Wright L, Hennings H, Yuspa SH. Inducible cutaneous inflammation reveals a protumorigenic role for keratinocyte CXCR2 in skin carcinogenesis. Cancer Res 2009, 69(1):319-328. 10.1158/0008-5472.CAN-08-2490, 2872171, 19118017.
36. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004, 6(5):447-458. 10.1016/j.ccr.2004.09.028, 15542429.
37. Hwang SG, Park J, Park JY, Park CH, Lee KH, Cho JW, Hwang JI, Seong JY. Anti-cancer activity of a novel small molecule compound that simultaneously activates p53 and inhibits NF-kappaB signaling. PLoS One 2012, 7(9):e44259. 10.1371/journal.pone.0044259, 3441512, 23028510.
38. Fontemaggi G, Dell'Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, Terrenato I, Mottolese M, Muti P, Domany E, Del Bufalo D, Strano S, Blandino G. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol 2009, 16(10):1086-1093. 10.1038/nsmb.1669, 19783986.
39. Sunaga N, Imai H, Shimizu K, Shames DS, Kakegawa S, Girard L, Sato M, Kaira K, Ishizuka T, Gazdar AF, Minna JD, Mori M. Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer. Int J Cancer 2012, 130(8):1733-1744. 10.1002/ijc.26164, 3374723, 21544811.
40. Rivas MA, Tkach M, Beguelin W, Proietti CJ, Rosemblit C, Charreau EH, Elizalde PV, Schillaci R. Transactivation of ErbB-2 induced by tumor necrosis factor alpha promotes NF-kappaB activation and breast cancer cell proliferation. Breast Cancer Res Treat 2009, 122(1):111-124.
41. Jijon HB, Buret A, Hirota CL, Hollenberg MD, Beck PL. The EGF receptor and HER2 participate in TNF-alpha-dependent MAPK activation and IL-8 secretion in intestinal epithelial cells. Mediators Inflamm 2012, 2012:207398. 3440955, 22988345.
42. Concin N, Zeillinger C, Tong D, Stimpfl M, König M, Printz D, Stonek F, Schneeberger C, Hefler L, Kainz C, Leodolter S, Haas OA, Zeillinger R. Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines. Breast Cancer Res Treat 2003, 79(1):37-46. 10.1023/A:1023351717408, 12779080.
43. Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, Wigler N, Keydar I, Ben-Baruch A. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 2002, 62(4):1093-1102.
44. Simstein R, Burow M, Parker A, Weldon C, Beckman B. Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med (Maywood) 2003, 228(9):995-1003.
45. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004, 83(3):249-289. 10.1023/B:BREA.0000014042.54925.cc, 14758095.
46. Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res 2005, 65(3):999-1006.
47. Pfeifer GP, Besaratinia A. Mutational spectra of human cancer. Hum Genet 2009, 125(5-6):493-506. 2824590, 19308457.
48. Chu PY, Li TK, Ding ST, Lai IR, Shen TL. EGF-induced Grb7 recruits and promotes Ras activity essential for the tumorigenicity of Sk-Br3 breast cancer cells. J Biol Chem 2010, 285(38):29279-29285. 10.1074/jbc.C110.114124, 2937960, 20622016.
49. Oeste CL, Díez-Dacal B, Bray F, García de Lacoba M, de la Torre BG, Andreu D, Ruiz-Sánchez AJ, Pérez-Inestrosa E, García-Domínguez CA, Rojas JM, Pérez-Sala D. The C-terminus of H-Ras as a target for the covalent binding of reactive compounds modulating Ras-dependent pathways. PLoS One 2011, 6(1):e15866. 10.1371/journal.pone.0015866, 3017061, 21253588.
50. Sulzmaier FJ, Valmiki MK, Nelson DA, Caliva MJ, Geerts D, Matter ML, White EP, Ramos JW. PEA-15 potentiates H-Ras-mediated epithelial cell transformation through phospholipase D. Oncogene 2012, 31(30):3547-3560. 10.1038/onc.2011.514, 3295902, 22105357.
51. Martinez-Salgado C, Fuentes-Calvo I, Garcia-Cenador B, Santos E, Lopez-Novoa JM. Involvement of H- and N-Ras isoforms in transforming growth factor-beta1-induced proliferation and in collagen and fibronectin synthesis. Exp Cell Res 2006, 312(11):2093-2106. 10.1016/j.yexcr.2006.03.008, 16624289.
52. Kubota Y, O'Grady P, Saito H, Takekawa M. Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK pathway and cell transformation. Nat Cell Biol 2011, 13(3):282-291. 10.1038/ncb2169, 21336309.
53. Gutierrez L, Magee AI, Marshall CJ, Hancock JF. Post-translational processing of p21ras is two-step and involves carboxyl-methylation and carboxy-terminal proteolysis. Embo J 1989, 8(4):1093-1098. 400919, 2663468.
54. Tsai FM, Shyu RY, Jiang SY. RIG1 inhibits the Ras/mitogen-activated protein kinase pathway by suppressing the activation of Ras. Cell Signal 2006, 18(3):349-358. 10.1016/j.cellsig.2005.05.005, 16005186.
55. Kho Y, Kim SC, Jiang C, Barma D, Kwon SW, Cheng J, Jaunbergs J, Weinbaum C, Tamanoi F, Falck J, Zhao Y. A tagging-via-substrate technology for detection and proteomics of farnesylated proteins. Proc Natl Acad Sci U S A 2004, 101(34):12479-12484. 10.1073/pnas.0403413101, 515085, 15308774.
56. Pons M, Tebar F, Kirchhoff M, Peiro S, de Diego I, Grewal T, Enrich C. Activation of Raf-1 is defective in annexin 6 overexpressing Chinese hamster ovary cells. FEBS Lett 2001, 501(1):69-73. 10.1016/S0014-5793(01)02635-7, 11457458.
57. Roebuck KA. Oxidant stress regulation of IL-8 and ICAM-1 gene expression: differential activation and binding of the transcription factors AP-1 and NF-kappaB (Review). Int J Mol Med 1999, 4(3):223-230.
58. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009, 27:693-733. 10.1146/annurev.immunol.021908.132641, 19302050.
59. Adcock IM. Transcription factors as activators of gene transcription: AP-1 and NF-kappa B. Monaldi Arch Chest Dis 1997, 52(2):178-186.
60. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449(7162):557-563. 10.1038/nature06188, 17914389.
61. Chakraborty G, Kumar S, Mishra R, Patil TV, Kundu GC. Semaphorin 3A suppresses tumor growth and metastasis in mice melanoma model. PLoS One 2012, 7(3):e33633. 10.1371/journal.pone.0033633, 3308985, 22448259.
62. Kuriyama S, Masui K, Kikukawa M, Sakamoto T, Nakatani T, Nagao S, Yamazaki M, Yoshiji H, Tsujinoue H, Fukui H, Yoshimatsu T, Ikenaka K. Complete cure of established murine hepatocellular carcinoma is achievable by repeated injections of retroviruses carrying the herpes simplex virus thymidine kinase gene. Gene Ther 1999, 6(4):525-533. 10.1038/sj.gt.3300869, 10476212.
63. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissiere F, Laune D, Roques S, Lazennec G. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 2007, 9(1):R15. 10.1186/bcr1648, 1851386, 17261184.
64. Si Q, Zhao ML, Morgan AC, Brosnan CF, Lee SC. 15-deoxy-Delta12,14-prostaglandin J2 inhibits IFN-inducible protein 10/CXC chemokine ligand 10 expression in human microglia: mechanisms and implications. J Immunol 2004, 173(5):3504-3513.
65. Perrot-Applanat M, Vacher S, Toullec A, Pelaez I, Velasco G, Cormier F, Saad Hel S, Lidereau R, Baud V, Bieche I. Similar NF-kappaB gene signatures in TNF-alpha treated human endothelial cells and breast tumor biopsies. PLoS One 2011, 6(7):e21589. 10.1371/journal.pone.0021589, 3130773, 21754991.
66. Solomon H, Brosh R, Buganim Y, Rotter V. Inactivation of the p53 tumor suppressor gene and activation of the Ras oncogene: cooperative events in tumorigenesis. Discov Med 2010, 9(48):448-454.
67. Hacke K, Rincon-Orozco B, Buchwalter G, Siehler SY, Wasylyk B, Wiesmuller L, Rosl F. Regulation of MCP-1 chemokine transcription by p53. Mol Cancer 2010, 9:82. 10.1186/1476-4598-9-82, 2864217, 20406462.
68. Tang X, Asano M, O'Reilly A, Farquhar A, Yang Y, Amar S. p53 is an important regulator of CCL2 gene expression. Curr Mol Med 2012, 12(8):929-943. 10.2174/156652412802480844, 3786129, 22804246.